Zanamivir should be inhaled, not nebulisedBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c131 (Published 13 January 2010) Cite this as: BMJ 2010;340:c131
- Barry A Eagel, clinical safety director1
- 1Clinical Monitoring Research Programme, SAIC-Frederick, NCI-Frederick, 5705 Industry Lane, Frederick, MD 21702-1201, USA
Jefferson and colleagues say that nebulisation is the route of administration for zanamivir.1 However, prescribers should be aware that the approved use of zanamivir in the United States and European Union is by inhalation, not nebulisation.2 3
The Food and Drug Administration recently issued a warning against using the inhalation formulation in a solubilised form for nebulised delivery,4 and letters have been sent to prescribers in the US proscribing the use of zanamivir by the nebulised route because of a reported death after administration this way.5
Cite this as: BMJ 2010;340:c131
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract No HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organisations imply endorsement by the US government.
Competing interests: None declared.